| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 15 | 2025 | 1000 | 3.930 |
Why?
|
| Cardiovascular Diseases | 17 | 2023 | 2059 | 3.680 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2024 | 120 | 3.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2021 | 741 | 2.900 |
Why?
|
| Eicosapentaenoic Acid | 6 | 2020 | 81 | 2.560 |
Why?
|
| Heart Failure | 12 | 2024 | 2391 | 2.550 |
Why?
|
| Stroke | 7 | 2023 | 1081 | 2.040 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2025 | 304 | 1.960 |
Why?
|
| Cholesterol, LDL | 6 | 2022 | 606 | 1.860 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 735 | 1.790 |
Why?
|
| Anticholesteremic Agents | 4 | 2022 | 239 | 1.510 |
Why?
|
| Troponin I | 3 | 2024 | 123 | 1.490 |
Why?
|
| Dyslipidemias | 3 | 2019 | 241 | 1.470 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2023 | 74 | 1.440 |
Why?
|
| Coronary Disease | 3 | 2023 | 683 | 1.220 |
Why?
|
| Hypercholesterolemia | 4 | 2020 | 237 | 1.200 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 87 | 1.160 |
Why?
|
| Inferior Wall Myocardial Infarction | 2 | 2018 | 8 | 1.160 |
Why?
|
| Stents | 2 | 2025 | 874 | 1.140 |
Why?
|
| Hypolipidemic Agents | 2 | 2020 | 189 | 1.120 |
Why?
|
| Lipids | 4 | 2019 | 560 | 1.120 |
Why?
|
| Coronary Angiography | 5 | 2024 | 486 | 1.080 |
Why?
|
| Coronary Artery Disease | 3 | 2025 | 891 | 1.040 |
Why?
|
| Electrocardiography | 4 | 2024 | 996 | 1.030 |
Why?
|
| Risk Factors | 22 | 2025 | 10893 | 0.990 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 1062 | 0.960 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 1035 | 0.960 |
Why?
|
| Ultrasonography, Interventional | 2 | 2025 | 208 | 0.940 |
Why?
|
| Multiple Sclerosis | 7 | 2023 | 382 | 0.900 |
Why?
|
| Humans | 78 | 2025 | 131930 | 0.880 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2020 | 24 | 0.850 |
Why?
|
| Brain Ischemia | 2 | 2023 | 277 | 0.850 |
Why?
|
| Myocardium | 3 | 2018 | 907 | 0.830 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 46 | 0.830 |
Why?
|
| Aged | 28 | 2025 | 21394 | 0.820 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 221 | 0.790 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2023 | 21 | 0.780 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2020 | 58 | 0.770 |
Why?
|
| Dietary Supplements | 3 | 2021 | 439 | 0.760 |
Why?
|
| Risk Assessment | 8 | 2025 | 3710 | 0.720 |
Why?
|
| Galectin 3 | 1 | 2021 | 37 | 0.700 |
Why?
|
| Cardiology | 3 | 2021 | 497 | 0.690 |
Why?
|
| Biomarkers | 9 | 2024 | 3373 | 0.690 |
Why?
|
| Lipid Regulating Agents | 1 | 2020 | 6 | 0.680 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2020 | 3 | 0.670 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2023 | 339 | 0.670 |
Why?
|
| Vascular Stiffness | 1 | 2021 | 80 | 0.660 |
Why?
|
| Denervation | 1 | 2020 | 30 | 0.660 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2022 | 1246 | 0.660 |
Why?
|
| Veterans | 3 | 2021 | 1762 | 0.640 |
Why?
|
| Middle Aged | 25 | 2025 | 28893 | 0.620 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2023 | 3852 | 0.600 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 111 | 0.600 |
Why?
|
| Eligibility Determination | 1 | 2019 | 38 | 0.600 |
Why?
|
| Troponin T | 4 | 2024 | 295 | 0.590 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 39 | 0.590 |
Why?
|
| Drug Costs | 1 | 2019 | 65 | 0.580 |
Why?
|
| Smoking Cessation | 1 | 2020 | 191 | 0.580 |
Why?
|
| Biological Products | 1 | 2020 | 137 | 0.580 |
Why?
|
| Docosahexaenoic Acids | 1 | 2019 | 66 | 0.580 |
Why?
|
| Incretins | 1 | 2018 | 24 | 0.550 |
Why?
|
| Anticoagulants | 3 | 2020 | 609 | 0.550 |
Why?
|
| Secondary Prevention | 1 | 2019 | 219 | 0.550 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 135 | 0.550 |
Why?
|
| Treatment Outcome | 12 | 2025 | 12996 | 0.540 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 380 | 0.540 |
Why?
|
| Cardiovascular System | 1 | 2018 | 106 | 0.530 |
Why?
|
| Pyrimidines | 1 | 2020 | 418 | 0.520 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 922 | 0.520 |
Why?
|
| Betacoronavirus | 1 | 2020 | 299 | 0.520 |
Why?
|
| United States | 16 | 2022 | 11619 | 0.510 |
Why?
|
| Kidney | 2 | 2020 | 1326 | 0.500 |
Why?
|
| Male | 33 | 2025 | 64846 | 0.490 |
Why?
|
| Pandemics | 2 | 2021 | 1185 | 0.490 |
Why?
|
| Genome-Wide Association Study | 6 | 2022 | 1830 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 378 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 389 | 0.460 |
Why?
|
| Hypertension | 2 | 2021 | 1386 | 0.450 |
Why?
|
| Peptide Fragments | 3 | 2023 | 797 | 0.450 |
Why?
|
| Female | 30 | 2025 | 70607 | 0.450 |
Why?
|
| Ezetimibe | 3 | 2019 | 94 | 0.440 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 482 | 0.420 |
Why?
|
| Hospitalization | 2 | 2019 | 1892 | 0.420 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 558 | 0.410 |
Why?
|
| Aged, 80 and over | 9 | 2023 | 7113 | 0.410 |
Why?
|
| Blood Pressure | 3 | 2024 | 1394 | 0.380 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2023 | 42 | 0.380 |
Why?
|
| Sitosterols | 2 | 2009 | 10 | 0.370 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2021 | 694 | 0.370 |
Why?
|
| Berberine | 2 | 2009 | 10 | 0.360 |
Why?
|
| Myocardial Revascularization | 2 | 2024 | 105 | 0.360 |
Why?
|
| Glucosides | 3 | 2020 | 48 | 0.350 |
Why?
|
| Tobacco, Smokeless | 2 | 2020 | 9 | 0.340 |
Why?
|
| Benzhydryl Compounds | 3 | 2020 | 68 | 0.340 |
Why?
|
| Dicarboxylic Acids | 3 | 2019 | 34 | 0.330 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 1159 | 0.330 |
Why?
|
| Prognosis | 6 | 2025 | 5004 | 0.320 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3082 | 0.310 |
Why?
|
| Europe | 2 | 2020 | 372 | 0.300 |
Why?
|
| Congresses as Topic | 2 | 2020 | 185 | 0.300 |
Why?
|
| Cholesterol | 2 | 2009 | 559 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1408 | 0.290 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 89 | 0.280 |
Why?
|
| Fatty Acids | 3 | 2019 | 356 | 0.280 |
Why?
|
| Triglycerides | 3 | 2022 | 617 | 0.280 |
Why?
|
| Phytosterols | 1 | 2008 | 28 | 0.280 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 303 | 0.280 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 2303 | 0.270 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 689 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2021 | 2850 | 0.250 |
Why?
|
| Heart Rate | 2 | 2018 | 587 | 0.230 |
Why?
|
| Time Factors | 4 | 2025 | 6435 | 0.230 |
Why?
|
| Angiopoietin-like Proteins | 2 | 2022 | 13 | 0.220 |
Why?
|
| Mutation | 1 | 2018 | 6245 | 0.220 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3735 | 0.210 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 159 | 0.210 |
Why?
|
| Meta-Analysis as Topic | 2 | 2018 | 172 | 0.210 |
Why?
|
| Fishes | 1 | 2023 | 36 | 0.210 |
Why?
|
| Interleukin-18 | 1 | 2023 | 68 | 0.200 |
Why?
|
| Biological Phenomena | 1 | 2023 | 3 | 0.200 |
Why?
|
| Postmenopause | 2 | 2020 | 153 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 1176 | 0.200 |
Why?
|
| Infusions, Intravenous | 1 | 2024 | 547 | 0.200 |
Why?
|
| HLA-DRB1 Chains | 2 | 2013 | 45 | 0.190 |
Why?
|
| Animals | 8 | 2023 | 34908 | 0.190 |
Why?
|
| Adult | 14 | 2025 | 31506 | 0.190 |
Why?
|
| HLA-B Antigens | 2 | 2012 | 30 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2023 | 6526 | 0.190 |
Why?
|
| Radial Artery | 1 | 2022 | 32 | 0.190 |
Why?
|
| Phenotype | 4 | 2021 | 4538 | 0.190 |
Why?
|
| Proprotein Convertase 9 | 1 | 2022 | 81 | 0.180 |
Why?
|
| HLA Antigens | 2 | 2021 | 219 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2023 | 435 | 0.180 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 51 | 0.180 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 1439 | 0.170 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 158 | 0.170 |
Why?
|
| Lipoprotein-X | 1 | 2020 | 3 | 0.170 |
Why?
|
| Tobacco Use | 1 | 2020 | 32 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 463 | 0.170 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2020 | 50 | 0.170 |
Why?
|
| Coronary Thrombosis | 1 | 2020 | 35 | 0.170 |
Why?
|
| Telecommunications | 1 | 2020 | 22 | 0.170 |
Why?
|
| Vitamin K | 1 | 2020 | 38 | 0.170 |
Why?
|
| Behavioral Risk Factor Surveillance System | 4 | 2021 | 50 | 0.170 |
Why?
|
| Oligonucleotides | 1 | 2020 | 95 | 0.160 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 110 | 0.160 |
Why?
|
| Antifibrinolytic Agents | 1 | 2020 | 49 | 0.160 |
Why?
|
| Guideline Adherence | 2 | 2019 | 396 | 0.160 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 79 | 0.160 |
Why?
|
| Tobacco Products | 1 | 2020 | 72 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2021 | 175 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 449 | 0.160 |
Why?
|
| Echocardiography | 2 | 2023 | 1125 | 0.160 |
Why?
|
| Vaping | 1 | 2020 | 30 | 0.160 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 80 | 0.160 |
Why?
|
| Multidetector Computed Tomography | 1 | 2019 | 39 | 0.160 |
Why?
|
| Protective Factors | 1 | 2020 | 90 | 0.160 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 57 | 0.160 |
Why?
|
| Angina Pectoris | 1 | 2019 | 68 | 0.160 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 81 | 0.150 |
Why?
|
| Heart Ventricles | 2 | 2021 | 784 | 0.150 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 26 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 155 | 0.150 |
Why?
|
| Radiation Dosage | 1 | 2019 | 146 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2019 | 50 | 0.150 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 3 | 0.150 |
Why?
|
| Schizophrenia | 1 | 2022 | 332 | 0.150 |
Why?
|
| RNAi Therapeutics | 1 | 2019 | 17 | 0.150 |
Why?
|
| Office Visits | 1 | 2019 | 78 | 0.150 |
Why?
|
| RNA Interference | 1 | 2020 | 516 | 0.150 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2018 | 19 | 0.150 |
Why?
|
| Bipolar Disorder | 1 | 2022 | 369 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2020 | 206 | 0.140 |
Why?
|
| Monocytes | 1 | 2020 | 342 | 0.140 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 341 | 0.140 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 215 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 311 | 0.140 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 40 | 0.140 |
Why?
|
| Young Adult | 4 | 2020 | 9929 | 0.140 |
Why?
|
| Paraplegia | 1 | 2018 | 96 | 0.140 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 120 | 0.140 |
Why?
|
| Cysts | 1 | 2018 | 97 | 0.140 |
Why?
|
| Hypertriglyceridemia | 1 | 2019 | 114 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 238 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1668 | 0.130 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2017 | 46 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 382 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 375 | 0.130 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 175 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 547 | 0.130 |
Why?
|
| Membrane Transport Proteins | 1 | 2018 | 182 | 0.130 |
Why?
|
| Cause of Death | 1 | 2019 | 500 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2019 | 1255 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2018 | 166 | 0.130 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2017 | 106 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2019 | 880 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 244 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 778 | 0.120 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 19 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2019 | 326 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 663 | 0.120 |
Why?
|
| Genotype | 2 | 2021 | 2703 | 0.120 |
Why?
|
| Incidence | 2 | 2025 | 3362 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 511 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 20524 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 463 | 0.120 |
Why?
|
| Aorta, Thoracic | 1 | 2020 | 540 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 528 | 0.120 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 491 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 234 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2019 | 549 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 269 | 0.110 |
Why?
|
| Action Potentials | 1 | 2018 | 495 | 0.110 |
Why?
|
| Patient Selection | 1 | 2019 | 730 | 0.110 |
Why?
|
| Recurrence | 3 | 2023 | 1451 | 0.110 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 203 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 680 | 0.110 |
Why?
|
| Testosterone | 1 | 2020 | 611 | 0.110 |
Why?
|
| Aging | 1 | 2022 | 1252 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2018 | 862 | 0.110 |
Why?
|
| Lipoproteins | 2 | 2022 | 188 | 0.110 |
Why?
|
| Macular Degeneration | 1 | 2016 | 127 | 0.110 |
Why?
|
| Alleles | 2 | 2021 | 1684 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 30 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2020 | 699 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2018 | 1596 | 0.090 |
Why?
|
| HLA-DP beta-Chains | 1 | 2012 | 10 | 0.090 |
Why?
|
| Major Histocompatibility Complex | 1 | 2012 | 53 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2018 | 5143 | 0.090 |
Why?
|
| Genome, Human | 3 | 2021 | 1331 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2016 | 937 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 5394 | 0.080 |
Why?
|
| Population Groups | 1 | 2010 | 31 | 0.080 |
Why?
|
| Amino Acids | 1 | 2013 | 626 | 0.080 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 408 | 0.080 |
Why?
|
| Immunologic Factors | 2 | 2022 | 184 | 0.080 |
Why?
|
| Prevalence | 3 | 2022 | 2656 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2017 | 3415 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 810 | 0.080 |
Why?
|
| Brain | 2 | 2022 | 3198 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 38 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 3358 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 33 | 0.080 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 43 | 0.080 |
Why?
|
| Child | 2 | 2020 | 25756 | 0.070 |
Why?
|
| HIV-1 | 1 | 2012 | 483 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2012 | 293 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2012 | 1118 | 0.070 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 16 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2009 | 436 | 0.070 |
Why?
|
| Disease Progression | 2 | 2023 | 2222 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4688 | 0.060 |
Why?
|
| Age Factors | 2 | 2025 | 2920 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 1604 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2018 | 4717 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 1579 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1224 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 1033 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17345 | 0.060 |
Why?
|
| Intermediate Filaments | 1 | 2023 | 10 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 626 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2023 | 40 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 14715 | 0.050 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2022 | 21 | 0.050 |
Why?
|
| Apolipoprotein C-III | 1 | 2022 | 46 | 0.050 |
Why?
|
| Rats | 1 | 2008 | 3606 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 105 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 45 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 356 | 0.040 |
Why?
|
| Atrophy | 1 | 2022 | 251 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 3977 | 0.040 |
Why?
|
| Haplotypes | 2 | 2013 | 545 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 51 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 122 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2023 | 802 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 200 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 180 | 0.040 |
Why?
|
| Acute Disease | 1 | 2023 | 1161 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 15 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2048 | 0.040 |
Why?
|
| Lisinopril | 1 | 2019 | 24 | 0.040 |
Why?
|
| Amlodipine | 1 | 2019 | 23 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2019 | 64 | 0.040 |
Why?
|
| Metoprolol | 1 | 2019 | 19 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 191 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 86 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 698 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 74 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 390 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 507 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 275 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2020 | 535 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 618 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2017 | 136 | 0.030 |
Why?
|
| Exome | 1 | 2022 | 1087 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 306 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 289 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2017 | 177 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 714 | 0.030 |
Why?
|
| Metagenomics | 1 | 2017 | 106 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1348 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 679 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 422 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 412 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 803 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 271 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 317 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1613 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1731 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1098 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 110 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3019 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3044 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 277 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2013 | 218 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 860 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2013 | 188 | 0.020 |
Why?
|
| Disease Resistance | 1 | 2012 | 27 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 1163 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 750 | 0.020 |
Why?
|
| Mice | 2 | 2018 | 18534 | 0.020 |
Why?
|
| Human Genome Project | 1 | 2010 | 55 | 0.020 |
Why?
|
| Absorption | 1 | 2009 | 51 | 0.020 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2009 | 15 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 856 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 234 | 0.020 |
Why?
|
| Cricetinae | 1 | 2009 | 381 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2009 | 104 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 447 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 197 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 229 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2009 | 309 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1045 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 1563 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 1799 | 0.010 |
Why?
|